S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
New CBOE “special perk” helps traders target income every weekend (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
Top-Rated StocksTop-Rated

DexCom (DXCM) Stock Price, News & Analysis

$116.97
-1.92 (-1.61%)
(As of 12/8/2023 ET)
Compare
Today's Range
$116.92
▼
$119.39
50-Day Range
$75.49
▼
$118.89
52-Week Range
$74.75
▼
$139.55
Volume
2.38 million shs
Average Volume
3.68 million shs
Market Capitalization
$45.19 billion
P/E Ratio
128.54
Dividend Yield
N/A
Price Target
$132.33
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

DexCom MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.93 Rating Score
Upside/​Downside
13.1% Upside
$132.33 Price Target
Short Interest
Healthy
4.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.88mentions of DexCom in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.20 M Sold Last Quarter
Proj. Earnings Growth
18.06%
From $1.44 to $1.70 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.96 out of 5 stars

Medical Sector

29th out of 940 stocks

Surgical & Medical Instruments Industry

8th out of 94 stocks

See Top Rated MarketRank™ Stocks Here

DXCM stock logo

About DexCom Stock (NASDAQ:DXCM)

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DXCM Stock Price History

DXCM Stock News Headlines

December 8, 2023 | americanbankingnews.com
Head-To-Head Review: DexCom (NASDAQ:DXCM) vs. Össur hf. (OTCMKTS:OSSFF)
December 7, 2023 | finance.yahoo.com
Veeva Systems (VEEV) Beats on Q3 Earnings, Revises FY24 Outlook
December 10, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
December 7, 2023 | finance.yahoo.com
DexCom Insiders Sold US$5.1m Of Shares Suggesting Hesitancy
December 7, 2023 | barrons.com
CORRECTING AND REPLACING:/ Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
December 6, 2023 | msn.com
Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think "Yes"
December 6, 2023 | finance.yahoo.com
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump
December 6, 2023 | americanbankingnews.com
DexCom (NASDAQ:DXCM) PT Raised to $122.00 at Morgan Stanley
December 10, 2023 | Autonomix (Ad)
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
December 5, 2023 | benzinga.com
Market Whales and Their Recent Bets on DXCM Options
December 5, 2023 | finance.yahoo.com
DexCom Stock Earns Healthy Relative Strength Rating Upgrade
December 5, 2023 | finance.yahoo.com
Insider Sell Alert: EVP Chief Legal Officer Michael Brown Sells 3,612 Shares of DexCom Inc (DXCM)
December 5, 2023 | americanbankingnews.com
DexCom, Inc. (NASDAQ:DXCM) EVP Michael Jon Brown Sells 3,612 Shares of Stock
December 5, 2023 | americanbankingnews.com
DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of "Moderate Buy" from Analysts
November 30, 2023 | finance.yahoo.com
11 Best Long Term Growth Stocks To Invest In
November 29, 2023 | benzinga.com
DexCom Stock (NASDAQ:DXCM) Insider Trades
November 25, 2023 | finance.yahoo.com
Insider Sell: EVP Chief Human Resources Officer Sadie Stern Sells Shares of DexCom Inc (DXCM)
November 23, 2023 | finance.yahoo.com
Here's Why You Should Retain Edward Lifesciences (EW) Stock Now
November 22, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Enanta Pharmaceuticals (ENTA) and Arvinas Holding Company (ARVN)
November 22, 2023 | finance.yahoo.com
DexCom's (NASDAQ:DXCM) 29% CAGR outpaced the company's earnings growth over the same five-year period
November 20, 2023 | finance.yahoo.com
DexCom (DXCM) is an Incredible Growth Stock: 3 Reasons Why
November 20, 2023 | insidermonkey.com
Investors’ Concerns over the Impact of GLP-1 Drugs Dragged DexCom (DXCM)
November 19, 2023 | finance.yahoo.com
2 Stock Split Growth Stocks to Buy and Hold
November 17, 2023 | msn.com
Reasons to Add DexCom (DXCM) Stock to Your Portfolio Now
November 17, 2023 | finance.yahoo.com
Obesity Drugs Put These Stocks on a Crash Diet—Now They’re Rebounding
November 14, 2023 | nasdaq.com
Dexcom Rings the Opening Bell
November 14, 2023 | finance.yahoo.com
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/26/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/08/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
CIK
1093557
Web
www.dexcom.com
Phone
(858) 200-0200
Fax
858-200-0201
Employees
7,600
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$132.33
High Stock Price Target
$160.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+13.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
15 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.91
Trailing P/E Ratio
128.54
Forward P/E Ratio
81.23
P/E Growth
2.46
Net Income
$341.20 million
Net Margins
11.08%
Pretax Margin
17.56%
Return on Equity
25.05%
Return on Assets
8.99%

Debt

Debt-to-Equity Ratio
1.07
Current Ratio
2.80
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$2.91 billion
Price / Sales
15.53
Cash Flow
$1.29 per share
Price / Cash Flow
90.77
Book Value
$5.52 per share
Price / Book
21.19

Miscellaneous

Outstanding Shares
386,370,000
Free Float
384,790,000
Market Cap
$45.19 billion
Optionable
Optionable
Beta
1.22

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of DexCom was last updated on Tuesday, November 28, 2023 at 10:07 AM.

Pros

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom, Inc. specializes in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. With the increasing prevalence of diabetes, there is a growing demand for CGM systems to help patients manage their blood sugar levels.
  • DexCom's products, such as the Dexcom G6 and Dexcom G7, offer real-time, continuous data on glucose levels, providing valuable insights for diabetes management.
  • The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. This partnership could lead to innovative advancements in CGM technology.
  • DexCom's Dexcom Real-Time API enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This opens up opportunities for partnerships and integrations with other healthcare technology companies.
  • Investors may find the current stock price of DexCom, Inc. attractive. Please note that the stock price is subject to market fluctuations and should be evaluated based on recent periods.

Cons

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • The surgical and medical instruments industry, in which DexCom operates, can be highly competitive. The company may face challenges from existing competitors or new entrants in the market.
  • While DexCom's CGM systems offer valuable data for diabetes management, the adoption of these systems may vary among healthcare providers and individuals with diabetes. Market acceptance and penetration could impact the company's growth potential.
  • As with any medical device company, DexCom is subject to regulatory approvals and compliance. Changes in regulations or delays in obtaining approvals could affect the company's ability to bring new products to market.
  • Investors should consider the financial performance and stability of DexCom, Inc. before making investment decisions. It is important to analyze the company's revenue growth, profitability, and cash flow to assess its long-term sustainability.
  • Market conditions and macroeconomic factors can also impact the performance of DexCom, Inc. Investors should stay informed about industry trends, healthcare policies, and economic indicators that may affect the company's prospects.














DXCM Stock Analysis - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

What is DexCom's stock price target for 2024?

15 Wall Street analysts have issued 1 year target prices for DexCom's shares. Their DXCM share price targets range from $100.00 to $160.00. On average, they anticipate the company's share price to reach $132.33 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2023?

DexCom's stock was trading at $113.24 at the start of the year. Since then, DXCM stock has increased by 3.3% and is now trading at $116.97.
View the best growth stocks for 2023 here.

Are investors shorting DexCom?

DexCom saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 17,750,000 shares, a drop of 15.7% from the October 31st total of 21,060,000 shares. Based on an average daily volume of 5,150,000 shares, the short-interest ratio is presently 3.4 days.
View DexCom's Short Interest.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our DXCM earnings forecast.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings data on Thursday, October, 26th. The medical device company reported $0.50 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $0.16. The medical device company earned $975 million during the quarter, compared to the consensus estimate of $939.64 million. DexCom had a trailing twelve-month return on equity of 25.05% and a net margin of 11.08%. DexCom's revenue was up 26.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.28 EPS.
Read the conference call transcript.

What ETFs hold DexCom's stock?

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS).

When did DexCom's stock split?

Shares of DexCom split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom updated its FY 2023 earnings guidance on Friday, September, 15th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

Who are DexCom's major shareholders?

DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.32%), Sands Capital Management LLC (3.54%), Blair William & Co. IL (1.17%), Jennison Associates LLC (1.11%), Northern Trust Corp (1.01%) and Clearbridge Investments LLC (0.84%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
This page (NASDAQ:DXCM) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -